CNS Oncology (Sep 2020)

Can 3D-CRT meet the desired dose distribution to target and OARs in glioblastoma? A tertiary cancer center experience

  • Narendra Kumar,
  • Srinivasa GY,
  • Chinna B Dracham,
  • Treshita Dey,
  • Renu Madan,
  • Divya Khosla,
  • Arun Oinum,
  • Rakesh Kapoor

DOI
https://doi.org/10.2217/cns-2020-0010
Journal volume & issue
Vol. 9, no. 3

Abstract

Read online

Aim: The purpose of the study is to perform a dosimetric analysis of the doses received by planning target volume and organ at risks in the postoperative glioblastoma by using 3D-conformal radiotherapy to a total dose of 60 Gy in 30 fractions. Materials & Methods: All patients received concurrent temozolomide every day, and this was followed by adjuvant temozolomide of 5 days of treatment per month. Results: More than 98% of patients were treated with a dose of 60 Gy. Doses were analyzed for the normal whole brain, tumor volume, as well as all the organs at risk. Conclusion: Given the grave prognosis and the limited survival of glioblastoma despite the best treatment available, makes 3D-conformal radiotherapy an equally acceptable treatment option.

Keywords